For international patients comparing radiotherapy options, China occupies an unusual position. Proton and heavy-ion therapy are delivered at a growing number of centres, the underlying clinical infrastructure is serious, and yet the three questions that actually decide a trip — is my tumour a candidate, how long will I wait, and what will the whole course cost — are rarely answered in one place. This guide is about those three questions, written for patients and families still in the deciding stage rather than for clinicians.
One clarification before anything else. Whether particle therapy is appropriate for you is a clinical judgement, not a search result. A specific treatment plan must be assessed in person, or at minimum through a documented remote review, by a licensed radiation oncologist who has seen your imaging and pathology. Nothing below substitutes for that assessment.
What extra capacity actually changes for an overseas patient
More proton and heavy-ion capacity changes access, not eligibility. The physics, the technical constraints and the requirement for physician review stay the same. What shifts is the practical picture:
- Consultation slots become easier to obtain. More machine time and more clinical staff generally mean more international-patient review slots, particularly outside the busiest sites.
- Second opinions become realistic. If one centre's review does not support a particle plan, another site may assess the same records independently. Getting two reviews is now more feasible than it used to be.
- Quotations become more comparable. You should still expect per-centre, per-case pricing, but collecting more than one written quote has become less of an expedition.
What does not change is that beam time is a finite resource everywhere. Patients are scheduled in blocks grouped by treatment site and fractionation scheme, and routine quality-assurance cycles or an unplanned machine stoppage can move a start date. If you are booking flights around a start date, treat that date as provisional until the centre's international office confirms it in writing. If you want the structural background first, our proton therapy in China guide covers how these programmes are organised, and the service overview covers what we arrange on the ground.
Proton versus heavy-ion, in plain terms
Both are particle beams, and both earn their place because of where they deposit energy. A photon (X-ray) beam loses dose along its whole path through the body; a proton beam releases most of its energy at a defined depth — the Bragg peak — with little beyond it, which spares tissue behind the target. Heavy ions, typically carbon, are heavier and behave differently again: they are less scattered and produce denser local energy deposition, which some tumour types respond to differently.
The honest way to frame this to yourself is spatial, not hierarchical. These beams are chosen when the tumour sits close to an organ that cannot comfortably take dose, or when the total energy that would pass through the body on a photon plan is unattractive. They are not a general upgrade to radiotherapy, and choosing one because the technology sounds newer is the most common way patients overspend on a decision that was never clinical.
Indications: when a particle-therapy opinion is worth pursuing
Referral patterns that commonly come up for review include tumours at the base of the skull and in the spine region, paediatric cases where long-term normal-tissue dose matters, lesions that have recurred in a previously irradiated area, ocular and head-and-neck tumours, certain sarcomas, and thoracic, liver or pancreatic targets where adjacent organs constrain the dose. Whether any of these apply to you is a determination the reviewing physician makes on your actual scans — the pattern is a reason to ask, not a conclusion.
Cases that are usually not served by a particle plan are those where disease is widely disseminated, where the primary treatment is systemic rather than local, or where a conventional photon plan already keeps dose to critical organs within acceptable limits. In that last group, switching modality can add waiting time and cost without a benefit you can point to.
How to test whether your case deserves the trip
Before you request anything, write down three things: the exact histological diagnosis, the precise anatomical description of the lesion and its distance from organs at risk, and everything that has already been done to you — surgery dates, drug regimens, and especially any prior radiotherapy with dose and field if it is documented. A centre that can answer from those three items will give you a real opinion. A centre that answers from a diagnosis name alone is giving you marketing, not medicine. Note that prior radiotherapy is the single most consequential detail and the one most often omitted from summaries; it frequently changes the plan entirely.
Wait times: what actually drives how soon you can start
There is no published queue you can read. The interval between deciding and starting is built from stages, each with its own bottleneck, and each responds to something you can control.
| Stage | What usually sets the duration | What you can actually control |
|---|---|---|
| Records review / remote opinion | Completeness of imaging and pathology in original digital format | Send DICOM files, not screenshots; include prior treatment summaries |
| First in-person consultation | Appointment availability at the centre | Book earlier than feels necessary; keep a buffer week |
| Simulation, CT/MRI, immobilisation | Scheduling of the simulation slot | Travel with all documents translated and organised |
| Treatment planning (dosimetry) | Physics-team workload and plan complexity | Expect this to be non-negotiable in duration; ask, do not compress |
| Insurance or self-funding clearance | Insurer turnaround, pre-authorisation requirements | Submit the itemised quote before committing to a date |
| First fraction and course | Cohort scheduling and machine QA windows | Confirm the start date in writing before booking return travel |
| Follow-up and reporting | Centre's review schedule | Agree remote follow-up in advance to shorten your stay |
The two stages that most often slip are records review and funding clearance, and they slip for reasons that have nothing to do with clinical demand. Incomplete imaging turns a two-week review into a month. A quote sent to an insurer after travel is booked rather than before turns a scheduling question into a financial one. Everything else on that list is largely the centre's process, and pressing it rarely helps.
Total cost: read the structure of a quote, not a headline number
We will not publish a figure here, and you should be suspicious of any page that does without stating exactly what it covers. A full-course quotation for proton or heavy-ion therapy in China is assembled from components, and two centres can present very different totals for the same clinical plan depending on which components they bundle.
| Cost component | What to ask before you compare centres |
|---|---|
| Consultation and records review | Is it chargeable, and does it credit toward treatment if you proceed? |
| Simulation and imaging | Are contrast studies and repeat imaging included or billed separately? |
| Treatment planning / dosimetry | Is one plan price included, and what happens if the plan must be revised? |
| Fraction delivery | Is the quote per fraction or per course, and who decides the fraction count? |
| Image guidance and immobilisation devices | Are masks, cushions and daily imaging itemised? |
| Supportive care | Are concurrent medications, labs and managing-physician visits inside the envelope? |
| Interpretation and coordination | Is medical translation included, or charged separately? |
| Visa, travel and extended stay | Which costs sit outside the hospital entirely? |
Two structural realities are worth internalising. First, the number of fractions is set by your radiation oncologist, not by a price list, so a per-fraction quotation is inherently a range. Second, a patient's total outlay is rarely only the hospital invoice — interpreter time, additional imaging, and a stay longer than originally planned are the usual overages, and they are predictable if you budget for them rather than discover them.
Comparing a China plan against treatment at home
A fair comparison is not "price here versus price there." It is total cost against total value: the full itemised hospital charge plus travel and accommodation plus the cost of time away from work and family, compared against what the same clinical decision would cost and take at home. On some indications the difference is decisive and worth the logistics. On others it is modest, and the coordination burden of cross-border radiotherapy is not worth it. Only a physician who has reviewed your records can tell you which side of that line you are on — which is exactly why a documented case review should come before any budgeting exercise. For the wider context on organising cancer care in China, see our cancer treatment service page and the complete medical tourism guide; if systemic therapy rather than radiotherapy is under discussion, CAR-T therapy costs in China explains a different pricing logic entirely.
A decision checklist for international patients
Work through these in order. Skipping ahead is where patients lose money.
- Get the diagnosis and staging documents into original digital format, with prior treatment history written out.
- Obtain at least one documented clinical opinion on whether particle therapy is indicated for your specific lesion.
- Request an itemised quotation, in writing, naming every component in the table above.
- Send that quotation to your insurer and ask for pre-authorisation in writing.
- Only then confirm a provisional start date, and book travel with a buffer week rather than a tight connection.
- Arrange medical interpretation and a named coordinator before arrival, not at the registration desk.
- Agree the follow-up schedule and who writes the report before you leave the country.
How OriEast supports this process
OriEast is not a clinical adviser and does not decide whether you are a candidate for proton or heavy-ion therapy. What we do is make the process legible and survivable: assembling and translating your medical records for centre review, arranging hospital appointments, providing medical interpreters for consultation and simulation visits, coordinating logistics around your fraction schedule, and keeping a written record of quotes and confirmations so that nothing you were told verbally disappears. If a case does not belong in a particle-therapy programme, we will tell you that it needs a physician's view rather than sell you a booking.
Submit your case for a documented case evaluation and we will help you prepare the records that a centre actually needs, then collect quotations so you can compare on structure rather than on a single number. For scheduling, translation and on-the-ground coordination, send an inquiry or contact us directly. The clinical decision belongs to a licensed physician; the practical execution does not have to belong to you alone.